$ACHC

Acadia Healthcare (ACHC) reported Q2 earnings above estimates, driven by higher patient admissions. The stock has surged 30.26% over 90 days and 111.48% year-to-date, but long-term returns remain negative. Analysts suggest the stock is modestly undervalued at $30.22, with a fair value estimate of $32.21, citing growth prospects and operational leverage. However, risks include Medicaid reimbursement pressures and legal costs.

Acadia Healthcare (ACHC) is discussed in relation to its 18.17X forward 12-month P/E versus an industry 11.35X. The article cites YTD share gains of 113.1% and a Zacks Rank #3 (Hold). Consensus for 2026 calls for EPS of $1.54 and revenue of $3.43B. ACHC raised 2026 adjusted EBITDA guidance to $590-$615M and expects incremental adjusted EBITDA of $200M versus 2025, while noting higher operating and legal expenses.

UBS cut its price target on Acadia Healthcare to $1.50 from $4.50 and kept a Neutral rating, according to the note published Aug. 14, 2026. The article frames the decision using UBS’s valuation, EPS revision, and visibility metrics.

Acute care: Revenue was $495 million, flat year over year but up 6% after normalizing for supplemental payments. Management cited strong volumes and admissions at existing acute facilities as well as newer joint-venture and de novo locations. Specialty care: Revenue was $134 million, up 4% sequentially from the first quarter. The business experienced the full-quarter impact of the New York Medicaid decision.

Acadia Healthcare (NASDAQ: ACHC) shares fell 13.3% after the company reported mixed Q2 results. Revenue was flat year over year, while adjusted EPS dropped to $0.38 from $0.83. The company beat headline revenue and EPS expectations and slightly raised full-year guidance, but investors focused on weaker underlying profitability trends.

Acadia Healthcare Co. (ACHC) reported Q2 net income of 12 cents per share and adjusted earnings of 38 cents per share, versus a Zacks mean estimate of 33 cents. Revenue was $865.8 million, above the $844.7 million forecast. Full-year guidance calls for EPS of $1.45 to $1.60 and revenue of $3.4 billion to $3.45 billion.

Acadia Healthcare (NASDAQ:ACHC) reported Q2 CY2026 revenue of $865.8 million, flat year on year but above expectations by about 2%, and non-GAAP adjusted EPS of $0.38, down from $0.83 but 9.7% above consensus. The company guided full-year revenue to about $3.43 billion. Shares fell about 1.3% to $32.18 after the report.

Acadia Healthcare Company, Inc. (ACHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_994474.htm EXHIBIT 99.1 ex_994474.htm Exhibit 99.1 ACADIA HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS AND UPDATES FULL YEAR 2026 FINANCIAL AND CASH FLOW GUIDANCE FRANKLIN, Tenn. (July 28, 2026 ) – Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASD

Biotech stocks hit 52-week highs on July 21, 2026, tied to clinical-trial updates and upcoming earnings. China Pharma Holdings (CPHI) surged over 790% to $19.19. Xencor (XNCR) closed at $21.25, up 8%. Eton Pharmaceuticals (ETON) reached $43.20. 10x Genomics (TXG) closed at $47.20. Acadia Healthcare (ACHC) hit $35.65 intraday.

Buckley Capital Advisors’ Q1 2026 investor letter said small- and mid-cap equities were difficult in the quarter, but its portfolio rose about 13.8% net month-to-date in April and 8.6% net year-to-date, with gains continuing into May. The firm cited Acadia Healthcare (NASDAQ: ACHC), which closed at $23.20 on May 29, 2026. Buckley said it trimmed ACHC after it became its largest 2026 contributor and noted CEO Debra “Debbie” Osteen’s reappointment.